Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 1.00 |
| ▸ | MAOB | P27338 | 4/20 | 0.76 |
| ▸ | PNMT | P11086 | 1/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28279881 | 0.98 | TAAR1 (0.96) | TAAR1MAOBPNMTHRH3ALOX5 | |
| SCHEMBL5471659 | 0.88 | TAAR1 (0.78) | TAAR1MAOBPNMTALOX5NOTUM | |
| SCHEMBL29011885 | 0.84 | TAAR1 (0.72) | TAAR1MAOBPNMTALOX5NOTUM | |
| SCHEMBL16394285 | 0.84 | TAAR1 (0.71) | TAAR1MAOBALOX5ESR2BACE1 | |
| SCHEMBL31491189 | 0.84 | TAAR1 (0.71) | TAAR1MAOBALOX5ESR2BACE1 | |
| SCHEMBL19043262 | 0.83 | MAOB (0.81) | TAAR1MAOBPNMTALOX5 | |
| SCHEMBL5952281 | 0.83 | TAAR1 (0.70) | TAAR1MAOBPNMTHRH3CYP2A6 | |
| SCHEMBL20669453 | 0.82 | TAAR1 (0.68) | TAAR1MAOBALOX5ESR2BACE1 | |
| SCHEMBL1623905 | 0.82 | TAAR1 (0.69) | TAAR1MAOBALOX5ESR2 | |
| SCHEMBL15037693 | 0.82 | TAAR1 (0.69) | TAAR1MAOBALOX5ESR2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109384732-A | The method for preparing -1 inhibitor of Microsomal prostaglandin E2 synthase | 南京理工大学 | 2019-02-26 | — | — | CN | claimed |
| CN-109384732-A | The method for preparing -1 inhibitor of Microsomal prostaglandin E2 synthase | 南京理工大学 | 2019-02-26 | — | — | CN | disclosed |
| CN-109384732-A | The method for preparing -1 inhibitor of Microsomal prostaglandin E2 synthase | 南京理工大学 | 2019-02-26 | — | — | CN | disclosed |
| CN-104892539-B | Novel synthesis method of iron-catalyzed 2-aryl benzoxazole compound | 苏州大学 | 2017-12-22 | — | — | CN | disclosed |
| CN-104892539-A | Novel synthesis method of iron-catalyzed 2-aryl benzoxazole compound | UNIV SOOCHOW | 2015-09-09 | — | — | CN | disclosed |
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-05-03 | — | — | US | disclosed |
| EP-2009004-A1 | NOVEL PIPERAZINE COMPOUND, AND USE THEREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | JAPAN TOBACCO INC. (JP) | 2008-04-03 | — | — | US | disclosed |
| US-5278191-A | Nervous system disorders | G. D. SEARLE & CO. (US) | 1994-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081818-A1 | therapeutic agent for hepatitis C; R)-4-(4-trifluoromethyl-benzenesulfonyl)-piperazine-1,3-dicarboxylic acid 3-(4-isopropyl-benzylamide) 1-pyridin-4-ylamide; enzyme inhibitors | HAVCR2, AADAC, DNPEP | TAAR1 2335/4885MAOB 2630/4885PNMT 1037/4885 |
| US-20120107273-A1 | NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR | POLR1C, POLR2E, POLR2H | TAAR1 3452/4885MAOB 2997/4885PNMT 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.